This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of 0% and 3.93%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for February 7th
by Zacks Equity Research
AMSC, META, CLX, IPA and KMPR have been added to the Zacks Rank #1 (Strong Buy) List on February 7, 2023.
New Strong Buy Stocks for February 5th
by Zacks Equity Research
EZPW, MOD, IPA, WDC and OSK have been added to the Zacks Rank #1 (Strong Buy) List on February 5, 2023.
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 19.44% and 2.56%, respectively, for the quarter ended October 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for October 23rd
by Zacks Equity Research
MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.
ImmunoPrecise Antibodies Ltd. (IPA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
ImmunoPrecise Antibodies Ltd. (IPA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of 35.29% and 7.09%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
InnovAge Holding Corp. (INNV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -200% and 1.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 9.33% and 1.22%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of -16.67% and 6.19%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Axonics Modulation Technologies (AXNX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 104.35% and 0.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 4.24% and 5.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?